Ypsomed
Innovative, high-quality and reliable products and services which allow patients to administer their own medication in a safe and simple way.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| CHF | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 15 % | 7 % | 10 % | 37 % | (3 %) | 6 % | 19 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 21 % | 28 % | 29 % | 25 % | 44 % | 46 % | 46 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 5 % | 10 % | 14 % | 12 % | 27 % | 27 % | 27 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 6 % | 4 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Ypsomed Holding AG operates as a prominent developer and manufacturer of injection and infusion systems tailored for self-medication, with a specialized focus on diabetes care. Established in 2003 as a spin-off from the Disetronic Group, the company is managed by CEO Simon Michel, son of the founder and former CEO Willy Michel, who established the predecessor company in 1984. The company's origins trace back to the Michel family's pioneering work in injection systems, which began with the creation of the first reusable injection pen. This legacy continues to shape Ypsomed's strategic direction. The company went public on the SIX Swiss Exchange in 2004.
The business is structured into two primary segments. The first, Ypsomed Delivery Systems (YDS), functions on a business-to-business model, supplying pharmaceutical and biotechnology firms with a portfolio of pens, autoinjectors, and pump systems for the administration of liquid medications. This division leverages its expertise in device engineering and manufacturing to create customized delivery solutions for its partners. The second segment, mylife Diabetescare, markets products directly to consumers, including patients, pharmacies, and hospitals. This direct-to-consumer arm offers a range of products for individuals with diabetes, such as the mylife YpsoPump, an insulin pump system designed for ease of use, and the mylife App for data management.
Headquartered in Burgdorf, Switzerland, Ypsomed maintains a global footprint with a network of production facilities, subsidiaries, and distribution partners across the world, employing a workforce that exceeds 2,000 individuals. The company generates revenue through the sale of its delivery devices to pharmaceutical clients and through the direct sale of its diabetes care products to end-users and healthcare providers. A significant milestone was the partnership with the American technology company Dexcom for the integration of its real-time glucose monitoring systems with Ypsomed's mylife App, enhancing its digital health ecosystem. The company is also expanding its manufacturing capabilities with new production facilities in Germany, Schwerin, and a high-tech plant in Solothurn, Switzerland, to meet the growing demand for its products, particularly autoinjectors.
Keywords: self-medication, injection systems, diabetes care, infusion systems, autoinjectors, insulin pumps, drug delivery, medtech, pharmaceutical partner, B2B medical devices
